Pharmaceutical Corruption Media ArticlesExcerpts of Key Pharmaceutical Corruption Media Articles in Major Media
Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
What should happen if a massive viral outbreak appears out of nowhere and the only possible treatment is an untested drug? And who should receive it? The two American missionaries who contracted the almost-always-fatal virus in West Africa were given access to an experimental drug cocktail called ZMapp. It consists of immune-boosting monoclonal antibodies that were extracted from mice exposed to bits of Ebola DNA. Now in isolation at an Atlanta hospital, they appear to be doing well. It’s an opportunity the 900 Africans who’ve died so far never had. The reasons for different treatment are partly about logistics, partly about economics and, partly about a lack of any standard policy for giving out untested drugs in emergencies. Before this outbreak, ZMapp had only been tested on monkeys. But privileged humans were always going to be the first ones to try it. ZMapp requires a lot of refrigeration and careful handling, plus close monitoring by experienced doctors and scientists—better to try it at a big urban hospital than in rural West Africa, where no such infrastructure exists. And the two Americans who got it in Africa had been infected for more than a week, making its efficacy completely unknown.
Note: For more on this, see concise summaries of deeply revealing health news articles from reliable major media sources.
Three of Britain’s leading Ebola specialists have said experimental treatments for the deadly Ebola virus must be offered to the people of West Africa, after two US aid workers were administered with the “cure” in Liberia. The two missionaries, Dr Kent Brantly and Nancy Writebol, are alive and now being cared for at a specialist isolation unit in Atlanta. Though the pair remain weak – and there is no way of knowing at this stage how much of a help the new drug has actually been – the fact that it was given to the two Americans has resulted in widespread criticism and recriminations in West Africa. Almost 900 people have died from the Ebola virus across Guinea, Liberia and Sierra Leone since the latest outbreak began in February this year. Some strains can have fatality rates of up to 90 per cent, though that of the current crisis appears to be around 60 per cent. Now Peter Piot, who discovered Ebola in 1976, David Heymann, the director of the Chatham House Centre on Global Health Security and Jeremy Farrar from the Wellcome Trust have said there are in fact several drugs and vaccines under study that could be used to combat the disease. Liberia’s assistant health minister, Tolbert Nyenswah, said that the news of Dr Brantly and Ms Writebol’s treatment had “made our job very difficult” as dying patients and their relatives in Africa request the same “cure”. The US aid workers were given ZMapp, a drug made from antibodies produced in a lab that has never gone through human trials or been approved by the US’s FDA Food and Drug Administration. Piot, Farrar and Heymann questioned why Africans were not being given the same chance.
Note: For more on this, see concise summaries of deeply revealing health news articles from reliable major media sources.
Just months after U.S. Congressman Bill Posey compared the Center for Disease Control (CDC)'s vaccine safety studies to the SEC's Bernie Madoff scandal, malfeasance in the CDC's studies of thimerosal-containing vaccines has, for the first time, been documented in peer-reviewed scientific literature. The journal BioMed Research International now provides direct evidence that the CDC's safety assurances about the mercury-containing preservative are not fact-based, according to the article's lead author, Brian Hooker. The paper [cites] over 165 studies that have found thimerosal to be harmful, including 16 studies that had reported [serious detrimental] outcomes in human infants and children. "Substantial scientific evidence exists and has existed for many years that the vaccine ingredient thimerosal is a developmental neurotoxin" says George Lucier, former Associate Director of the National Toxicology Program. Studies showing harm from thimerosal sharply contradict published outcomes of six CDC coauthored and sponsored papers – the very studies that CDC relies upon to declare that thimerosal is "safe" for use in infant and maternal vaccines. Dr. Hooker ... said of the six CDC studies, "Each of these papers is fatally flawed from a statistics standpoint and several of the papers represent issues of scientific malfeasance. For example, important data showing a relationship between thimerosal exposure and autism are withheld from three of the publications. This type of cherry-picking of data by the CDC in order to change the results of important research studies to support flawed and dangerous vaccination policies should not be tolerated."
Note: A Reuters article reports that the former head of the US's CDC was later named president of Merck's vaccine division with accompanying high salary. Could this be payoff for her support in suppressing studies that cast doubt on vaccines? For more on this, see concise summaries of deeply revealing vaccines news articles from reliable major media sources.
Researchers who have fought for years to get full data on Roche's flu medicine Tamiflu said on Thursday that governments who stockpile it are wasting billions of dollars on a drug whose effectiveness is in doubt. In a review of trial data on Tamiflu, and on GlaxoSmithKline's flu drug Relenza, scientists from the respected research network the Cochrane Review said that the medicines had few if any beneficial effects, but did have adverse side effects. "Remember, the idea of a drug is that the benefits should exceed the harms," Heneghan said. "So if you can't find any benefits, that accentuates the harm." Tamiflu sales hit almost $3 billion in 2009 - mostly due to its use in the H1N1 flu pandemic. The drug, one of a class of medicines known as neuraminidase inhibitors, is approved by regulators worldwide and is stockpiled in preparation for a potential global flu outbreak. It is also on the World Health Organization's "essential medicines" list. The United States has spent more than $1.3 billion buying a strategic reserve of antivirals including Tamiflu, while the British government has spent almost 424 million pounds ($703 million) on a stockpile of some 40 million Tamiflu doses. There was no evidence of a reduction in hospitalizations or in flu complications ... and Tamiflu also increased the risk of nausea and vomiting in adults by around 4 percent and in children by 5 percent.
Note: For more along these lines, see concise summaries of deeply revealing health corruption news articles from reliable major media sources. For more along these lines, see the excellent, reliable resources provided in our Health Information Center.
The drug Tamiflu, given to tens of thousands of people during the swine flu pandemic, does nothing to halt the spread of influenza and the [UK] Government wasted nearly Ł500 million stockpiling it, a major study has found. The review, authored by Oxford University, claims that Roche, the drug’s Swiss manufacturer, gave a “false impression” of its effectiveness and accuses the company of “sloppy science”. The study found that Tamiflu, which was given to 240,000 people in the UK at a rate of 1,000 a week, has been linked to suicides of children in Japan and suggested that, far from easing flu symptoms, it could actually worsen them. Roche claimed at the time of the 2009 swine flu outbreak that trials had shown that it would reduce hospital admissions and complications such as pneumonia, bronchitis or sinusitis. Based on [these claims], the Department of Health bought around 40 million doses of Tamiflu at a cost of Ł424 million and prescribed it to around 240,000 people. In 2009, 0.5 per cent of the entire NHS budget was spent on the drug. However, researchers from The Cochrane Collaboration, a not-for-profit organisation which carries out reviews of health data, found that Tamiflu only cut flu-like symptoms from seven days to 6.3 days and there was no evidence of a reduction in hospital admissions. Eight children who took the drug in Japan ended up committing suicide after suffering psychotic episodes. Other side effects included kidney problems, nausea, vomiting and headaches. Many people reported feeling anxious or depressed when taking the drug.
Note: We sent out numerous messages at the time of all the fear-mongering around the avian and swine flu scares that this was wasting huge amounts of money. Of course the money wasn't just wasted, much of it went into the pockets of Donald Rumsfeld and others, as reported in this newspaper article. For the revealing news articles we compiled showing the blatant greed and corruption involved, click here.
The Medicare program is the source of a small fortune for many U.S. doctors, according to a trove of government records that reveal unprecedented details about physician billing practices nationwide. The government insurance program for older people paid nearly 4,000 physicians in excess of $1 million each in 2012, according to the new data. The release of the information gives the public access for the first time to the billing practices of individual doctors nationwide. Consumer groups and news outlets have pressured Medicare to release the data for years. The American Medical Association and other physician groups have resisted the data release, arguing that the information violates doctor privacy and that the public may misconstrue details about individual doctors. Among the highest billers were: a cardiologist in Ocala, Fla., who took in $18.1 million, mainly putting in stents; a New Jersey pathologist who received $12.6 million performing tissue exams and other tests; and a Michigan vascular surgeon who got $10.1 million. In some instances, the extremely high billing totals could signal fraudulent doctor behavior, as government inspectors have previously found. Indeed, three of the top 10 earners already had drawn scrutiny from the federal government, and one of them is awaiting trial on federal fraud charges. The greatest tallies also may signal that the Medicare payments for some procedures are too high for the amount of work involved or that perverse incentives lead doctors to overuse a procedure. The specialties most common at the top ranks of the Medicare payments were ophthalmologists, oncologists and pathologists.
Note: For more on medical corruption, see the deeply revealing reports from reliable major media sources available here.
Patients who suffered brain damage as a result of taking a swine flu vaccine are to receive multi-million-pound payouts from the UK government. Following the swine flu outbreak of 2009, about 60 million people, most of them children, received the vaccine. It was subsequently revealed that the vaccine, Pandemrix, can cause narcolepsy and cataplexy in about one in 16,000 people, and many more are expected to come forward with the symptoms. Across Europe, more than 800 children are so far known to have been made ill by the vaccine. The Pandemrix vaccine was manufactured by pharmaceuticals giant Glaxo Smith Kline, which refused to supply governments unless it was indemnified against any claim for damage caused. "There's no doubt in my mind whatsoever that Pandemrix increased the occurrence of narcolepsy onset in children," Emmanuelle Mignot, a specialist in sleep disorder at Stanford University in the United States told Reuters. Among those affected are NHS medical staff, many of whom are now unable to do their jobs because of the symptoms brought on by the vaccine. They will be suing the government for millions in lost earnings. However, the vast majority of patients affected - around 80% - are children. Despite a 2011 warning from the European Medicines Agency against using the vaccine on those under 20 and a study indicating a 13-fold heightened risk of narcolepsy in vaccinated children, GSK has refused to acknowledge a link.
Note: Read about people in other countries who were damaged by the vaccine on this webpage. See powerful media reports suggesting that both the avian flu and swine flu were manipulated to promote fear and boost pharmaceutical sales. And watch a powerful CBS video describing how 4,000 Americans in 1976 sued for neurological damages caused by a swine flu vaccine that they agreed to take after falling for fear mongering about the flu by the government. 300 people allegedly died from the vaccine. For more, see the excellent resources in our Health Information Center.
China has fined UK pharmaceuticals firm GlaxoSmithKline $490m (Ł297m) after a court found it guilty of bribery. The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted. The court gave GSK's former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and he is set to be deported. Other GSK executives have also been given suspended jail sentences. The guilty verdict was delivered after a one-day trial at a court in Changsha, according to the Xinhua news agency. Chinese authorities first announced they were investigating GSK in July last year, in what has become the biggest corruption scandal to hit a foreign firm in years. The company was accused of having made an estimated $150m in illegal profits. GSK said it had "published a statement of apology to the Chinese government and its people". This is a humiliating outcome for one of Britain's biggest companies: pleading guilty to systematic bribery, facing the biggest fine in Chinese history and making an abject apology to the Chinese government and people.
Note: In February 2016, GlaxoSmithKline was fined another $53 million by the UK for preventing generic competition. The list of huge fines to top drug companies includes five fines of over $1 billion and dozens over $100 million. How can we trust these companies on the safety and reliability of their products?
High-dose vitamin C can boost the cancer-killing effect of chemotherapy in the lab and mice, research suggests. Given by injection, it could potentially be a safe, effective and low-cost treatment for ovarian and other cancers. US scientists ... call for large-scale government clinical trials. Vitamin C has long been used as an alternative therapy for cancer. In the 1970s, chemist Linus Pauling reported that vitamin C given intravenously was effective in treating cancer. However, clinical trials of vitamin C given by mouth failed to replicate the effect, and research was abandoned. It is now known that the human body quickly excretes vitamin C when it is taken by mouth. However, scientists at the University of Kansas say that when given by injection vitamin C is absorbed into the body, and can kill cancer cells without harming normal ones. The researchers injected vitamin C into human ovarian cancer cells in the lab, into mice, and into patients with advanced ovarian cancer. They found ovarian cancer cells were sensitive to vitamin C treatment, but normal cells were unharmed. The treatment worked in tandem with standard chemotherapy drugs to slow tumour growth. "Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies," said lead researcher Qi Chen. "We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C."
Note: Read more about this amazing cancer research. For more along these lines, see concise summaries of deeply revealing news articles on promising cancer research that has been suppressed by the medical industry.
The British drug maker GlaxoSmithKline will no longer pay doctors to promote its products and will stop tying compensation of sales representatives to the number of prescriptions doctors write, its chief executive said ..., effectively ending two common industry practices that critics have long assailed as troublesome conflicts of interest. The announcement appears to be a first for a major drug company — although others may be considering similar moves — and it comes at a particularly sensitive time for Glaxo. It is the subject of a bribery investigation in China, where authorities contend the company funneled illegal payments to doctors and government officials in an effort to lift drug sales. For decades, pharmaceutical companies have paid doctors to speak on their behalf at conferences and other meetings of medical professionals, on the assumption that the doctors are most likely to value the advice of trusted peers. But the practice has also been criticized by those who question whether it unduly influences the information doctors give each other and can lead them to prescribe drugs inappropriately to patients. Under the plan, which Glaxo said would be completed worldwide by 2016, the company will no longer pay health care professionals to speak on its behalf about its products or the diseases they treat “to audiences who can prescribe or influence prescribing.” It will also stop providing financial support directly to doctors to attend medical conferences, a practice that is prohibited in the United States through an industry-imposed ethics code but that still occurs in other countries.
After more than 50 years leading the fight to legitimize attention deficit hyperactivity disorder, Keith Conners could be celebrating. Severely hyperactive and impulsive children, once shunned as bad seeds, are now recognized as having a real neurological problem. Doctors and parents have largely accepted drugs like Adderall and Concerta to temper the traits of classic A.D.H.D., helping youngsters succeed in school and beyond. But Dr. Conners did not feel triumphant this fall as he addressed a group of fellow A.D.H.D. specialists in Washington. He noted that recent data from the Centers for Disease Control and Prevention show that the diagnosis had been made in 15 percent of high school-age children, and that the number of children on medication for the disorder had soared to 3.5 million from 600,000 in 1990. He questioned the rising rates of diagnosis and called them “a national disaster of dangerous proportions.” “The numbers make it look like an epidemic. Well, it’s not. It’s preposterous,” Dr. Conners, a psychologist and professor emeritus at Duke University, said in a subsequent interview. “This is a concoction to justify the giving out of medication at unprecedented and unjustifiable levels.” The rise of A.D.H.D. diagnoses and prescriptions for stimulants over the years coincided with a remarkably successful two-decade campaign by pharmaceutical companies to publicize the syndrome and promote the pills to doctors, educators and parents. With the children’s market booming, the industry is now employing similar marketing techniques as it focuses on adult A.D.H.D., which could become even more profitable.
Note: For more on corruption in the medical industry, see the deeply revealing reports from reliable major media sources available here.
In a medical system notorious for opaque finances and inflated bills, nothing is more convoluted than hospital pricing, economists say. Hospital charges represent about a third of the $2.7 trillion annual United States health care bill, the biggest single segment, according to government statistics, and are the largest driver of medical inflation, a new study in The Journal of the American Medical Association found. A day spent as an inpatient at an American hospital costs on average more than $4,000, five times the charge in many other developed countries, according to the International Federation of Health Plans, a global network of health insurance industries. The most expensive hospitals charge more than $12,500 a day. And at many of them ... emergency rooms are profit centers. That is why one of the simplest and oldest medical procedures — closing a wound with a needle and thread — typically leads to bills of at least $1,500 and often much more. At Lenox Hill Hospital in New York City, Daniel Diaz, 29, a public relations executive, was billed $3,355.96 for five stitches on his finger after cutting himself while peeling an avocado. At a hospital in Jacksonville, Fla., Arch Roberts Jr., 56, a former government employee, was charged more than $2,000 for three stitches after being bitten by a dog. Insurers and patients negotiated lower prices, but those charges were a starting point. The main reason for high hospital costs in the United States, economists say, is fiscal, not medical: Hospitals are the most powerful players in a health care system that has little or no price regulation in the private market.
Note: For more on corruption in the health industry, see the deeply revealing reports from reliable major media sources available here.
It is one of the most common components of emergency medicine: an intravenous bag of sterile saltwater. Luckily for anyone who has ever needed an IV bag to replenish lost fluids or to receive medication, it is also one of the least expensive. The average manufacturer’s price, according to government data, has fluctuated in recent years from 44 cents to $1. Yet there is nothing either cheap or simple about its ultimate cost, as [revealed by] the commercial path of IV bags from the factory to the veins of more than 100 patients struck by a May 2012 outbreak of food poisoning in upstate New York. Some of the patients’ bills would later include markups of 100 to 200 times the manufacturer’s price, not counting separate charges for “IV administration.” And on other bills, a bundled charge for “IV therapy” was almost 1,000 times the official cost of the solution. At every step from manufacturer to patient, there are confidential deals among the major players, including drug companies, purchasing organizations and distributors, and insurers. These deals so obscure prices and profits that even participants cannot say what the simplest component of care actually costs, let alone what it should cost. And that leaves taxpayers and patients alike with an inflated bottom line and little or no way to challenge it. The real cost of a bag of normal saline, like the true cost of medical supplies from gauze to heart implants, disappears into an opaque realm of byzantine contracts, confidential rebates and fees that would be considered illegal kickbacks in many other industries.
Note: For more on this, see concise summaries of deeply revealing medical corruption news articles from reliable major media sources.
In ... the Journal of Law, Medicine and Ethics (JLME), Donald W. Light of the School of Public Health, University of Medicine & Dentistry of NJ, wrote an article entitled “Risky Drugs: Why The FDA Cannot Be Trusted”. The bulk of his essay focuses not on his views about pharma’s competence but rather on his issues with the FDA. While I found a number of his comments troubling, the following stood out. “The ... article in JLME also presents systematic, quantitative evidence that since the industry started making large contributions to the FDA for reviewing its drugs, as it makes large contributions to Congressmen ... drugs approved are significantly more likely to cause serious harm, hospitalizations, and deaths.” This is a pretty damning comment. Basically, Light is saying that pharma paid congressmen to sponsor legislation that results in the FDA being beholden to pharma for funding for its work. Implicit in this is that, as a result of these large “contributions”, the grateful FDA is rapidly approving medicines that are harmful.
Recent news out of China raises the question once again of whether any aspect of the pharmaceutical business can be trusted. First, Chinese authorities announced they were investigating GlaxoSmithKline and other pharma companies for bribing doctors, hospitals and government officials to buy and prescribe their drugs. Glaxo is accused of using a Shanghai travel agency to funnel at least $489 million in bribes. Then the New York Times revealed last week the alarming news that an internal Glaxo audit found serious problems with the way research was conducted at the company’s Shanghai research and development center. Last year Glaxo paid $3 billion to resolve civil and criminal allegations of, among other things, marketing widely used prescription drugs for unapproved treatments and using kickbacks to promote sales. Glaxo is a leader in pharma fraud and wrongdoing, with other industry heavyweights close behind. Over the past decade, whistleblowers and government investigations in the US have exposed a never-ending series of problems by numerous pharma companies in all facets of the industry, starting with fraudulent “research” papers used to bolster marketing and continuing through to the manufacture of contaminated and defective products, the marketing of drugs for unapproved and life-threatening uses and the mispricing of prescription drugs. Pharma ... has paid more than $30.2 billion in civil and criminal penalties to the US and state governments and continues to face more allegations of wrongdoing. The industry – despite huge penalties and a long string of public mea culpas – has a fraud habit that is just too profitable to kick. Finding a cure should be a top priority of regulators worldwide.
Note: For more on pharmaceutical industry corruption, see the deeply revealing reports from reliable major media sources available here.
Of all the oddities of the U.S. health care system, one stands out: we spend far more on health care per person than other industrialized nations yet have no better health outcomes. Understanding why isn’t easy. A 2012 paper by the Commonwealth Fund found that among 13 industrialized countries studied, the U.S. has the highest rate of obesity, which is usually a factor in higher health care costs. Yet, the U.S. ranks far behind many other countries in our rates of citizens who smoke or are over 55, two other strong indicators of increased spending. So why is our health care spending more than 17% of our gross domestic product, far more than any other country? A central reason U.S. health care spending is so high is that hospitals and doctors charge more for their services and there’s little transparency about why. There is no uniformity to the system, in which public and private insurers have separate, unrelated contracts with hospitals and doctors. The result is a tangled, confusing and largely secretive collection of forces driving health care prices higher and higher. This isn’t possible in many other countries either because governments set prices for health care services or broker negotiations between coalitions of insurers and providers. Known as “all-payer rate setting,” insurers in these systems band together to negotiate as groups. In contrast, U.S. insurers closely guard the secrecy of their contracted prices with health care providers and negotiate individually. This is why a hospital hosting five patients for knee replacements might get paid five different amounts for the surgeries.
Note: For more on corporate corruption, see the deeply revealing reports from reliable major media sources available here.
Peter Doshi ... is one of the most influential voices in medical research today. Dr. Doshi’s renown comes not from solving the puzzles of cancer or discovering the next blockbuster drug, but from pushing the world’s biggest pharmaceutical companies to open their records to outsiders. Together with a band of far-flung researchers and activists, he is trying to unearth data from clinical trials — complex studies that last for years and often involve thousands of patients across many countries — and make it public. The current system, the activists say, is one in which the meager details of clinical trials published in medical journals, often by authors with financial ties to the companies whose drugs they are writing about, is insufficient to the point of being misleading. For years, researchers have talked about the problem of publication bias, or selectively publishing results of trials. Concern about such bias gathered force in the 1990s and early 2000s, when researchers documented how, time and again, positive results were published while negative ones were not. Taken together, studies have shown that results of only about half of clinical trials make their way into medical journals. In 2009, Dr. Doshi and his colleagues set out to answer a simple question about the anti-flu drug Tamiflu: Does it work? Resolving that question has been far harder than they ever envisioned, and, four years later, there is still no definitive answer.
Note: If the public is going to be taking these drugs, shouldn't all safety studies be publicly available? What are the drug companies hiding? For more on corruption in the pharmaceutical industry, see the deeply revealing reports from reliable major media sources available here.
Drug companies face accusations of secretly colluding with pharmacists to overcharge the NHS millions of pounds, following an undercover investigation by The Telegraph. Pharmaceutical firms appear to have rigged the market in so-called "specials" – prescription drugs that are largely not covered by national NHS price regulations. The prices of more than 20,000 drugs could have been artificially inflated, with backhanders paid to chemists who agreed to sell them. Representatives of some companies agreed to invoice chemists for drugs at up to double their actual cost. Chemists would then send inflated invoices to the NHS, allowing them to pocket the difference. Tens of thousands of the "special" drugs are not on the nationally controlled NHS price list and so costs can be manipulated by drug companies. Sales representatives for drug firms were secretly recorded by this newspaper offering to provide apparently falsified invoices allowing chemists to bill the NHS for sums far greater than they would spend. Another firm offered to pay an annual fee to chemists who agreed to offer its prescription drugs. Hundreds of millions of pounds of taxpayers money are feared to have been wasted in recent years due to the practice. The undercover investigation was launched after this newspaper was approached by a whistle-blower who alleged widespread malpractice. Undercover reporters posed as investors hoping to set up a chain of chemists.
Note: Watch the incriminating videos of these undercover deals at the link above. For more on pharmaceutical corruption, see the deeply revealing reports from reliable major media sources available here.
The CDC pledges “To base all public health decisions on the highest quality scientific data.” In the case of influenza vaccinations and their marketing, this is not so. Promotion of influenza vaccines is one of the most visible and aggressive public health policies today. Although proponents employ the rhetoric of science, the studies underlying the policy are often of low quality, and do not substantiate officials’ claims. The vaccine might be less beneficial and less safe than has been claimed, and the threat of influenza appears overstated. Twenty years ago, in 1990, 32 million doses of influenza vaccine were available in the United States. Today [the number is] around 135 million doses. This enormous growth has not been fueled by popular demand but instead by a public health campaign. Drug companies have long known that to sell some products, you would have to first sell people on the disease. In the 1950s and 1960s, Merck launched an extensive campaign to lower the diagnostic threshold for hypertension, and in doing so enlarging the market for its diuretic drug, Diuril. Could influenza ... be yet one more case of disease mongering? Marketing influenza vaccines ... involves marketing influenza as a threat of great proportions. The CDC’s website explains that “Flu seasons ... can be severe,” citing a death toll of “3000 to a high of about 49000 people.” However, a far less volatile and more reassuring picture of influenza seems likely if one considers that recorded deaths from influenza declined sharply over the middle of the 20th century ... all before the great expansion of vaccination campaigns in the 2000s. Yet across the country, mandatory influenza vaccination policies have cropped up ... precisely because not everyone wants the vaccination, and compulsion appears the only way to achieve high vaccination rates.
Note: Read the entire revealing article at this link. The author clearly shows how fear and profit are the driving force behind flu vaccines and not good science and health. And this US government webpage states, "Since the first National Vaccine Injury Compensation (VICP) claims were filed in 1989, 3,981 compensation awards have been made. More than $2.8 billion in compensation awards has been paid to petitioners." For other verifiable information on health corruption, see the excellent, reliable resources provided in our Health Information Center.
Acting on the suggestion of her top data crunchers at the department’s Centers for Medicare and Medicaid Services (CMS), Health and Human Services Secretary Kathleen Sebelius released an enormous data file on May 8 that reveals the list—or “chargemaster”—prices of all hospitals across the country for the 100 most common inpatient treatment services in 2011. It then compares those prices with what Medicare actually paid hospitals for the same treatments—which was typically a fraction of the chargemaster prices. As a result, Americans are a big step closer to being able to compare what hospitals charge them for goods and services with what they actually cost. There are two reasons Sebelius’ release of this newly crunched, massive data file is a great first step toward a new transparency in health care costs. First, it reveals the vast disparity between what hospitals charge for pills, procedures and operations and the real cost of those services, as calculated by Medicare. The second reason the compilation and release of this data is a big deal is that it demonstrates [that] most hospitals’ chargemaster prices are wildly inconsistent and seem to have no rationale. Thus the release of this fire hose of data—which prints out at 17,511 pages—should become a tip sheet for reporters in every American city and town, who can now ask hospitals to explain their pricing. In the through-the-looking-glass world of health care economics, those who are asked to pay chargemaster rates are often under-insured or lack insurance altogether. Moreover, insurers typically negotiate discounts off the grossly inflated chargemaster prices ($77 for a box of gauze pads!), so the chargemaster matters for insured patients too.
Note: For more on corporate corruption, see the deeply revealing reports from reliable major media sources available here.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.